We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $-0.66 | — | — | $19.36M | — | 예정 |
| FY2025 Q3 | 2025. 09. 30. | 시각 미정 | — | $-1.8 | — | — | $50.15M | 보고됨 |
| FY2025 Q2 | 2025. 06. 30. | 시각 미정 | — | $-1.18 | — | — | $29.4M |
Consensus PT $31.17 · 12 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 14. | Lake Street | — | 커버리지 개시 | — → Buy | — | Lake Street: Buy |
| 2026. 03. 25. | Mizuho | — | 의견 유지 | Outperform → Outperform | — | Mizuho: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.59 | — | — | $14.11M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 471,794 | $4.9B | 0.01% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 357,955 | $2.91B | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 富途牛牛
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) ChartMill
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - 富途牛牛
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 富途牛牛
Kura Oncology Stock Hits Day Low of $10.39 Amid Price Pressure - Markets Mojo
Kura Oncology Stock Hits Day Low of $10.39 Amid Price Pressure Markets Mojo
Citizens reiterates Kura Oncology stock rating on FTI platform progress - Investing.com
Citizens reiterates Kura Oncology stock rating on FTI platform progress Investing.com
Citizens reiterates Kura Oncology stock rating on FTI platform progress By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on FTI platform progress By Investing.com Investing.com South Africa